Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Inclusion Criteria: * 1\. had non-metastatic high risk UTUC and planed to receive surgery(defined as high grade UTUC either by endoscopic biopsy or urinary cytology and/or any invasive aspect on radiological examination and/or hydronephrosis ); * 2\. were ineligible for cisplatin-based chemotherapy(defined as meeting at least one of the following criteria: Eastern Cooperative Oncology Group \[ECOG\] performance status 2, creatinine clearance 30-60 mL/min, grade ≥2 audiometric hearing loss, grade ≥2 peripheral neuropathy, or New York Heart Association Class III heart failure); * 3\. had not received any systemic anti-tumor therapy; * 4\. Adequate organ function defined by study-specified laboratory tests; Hemoglobin ≥90 g/L; Hematological Absolute neutrophil count (ANC) ≥1.5×109 /L; Platelets ≥100×109 /L * 5\. No functional organic disease: T-BIL≤1.5×upper limit of normal (ULN); ALT andAST≤2.5×ULN; Serum creatinine≤2×ULN; endogenous creatinine clearance rate\>30ml/min * 6\. Agree to comply with scheduled visits, treatment plans, lab tests and any other required study procedures; Exclusion Criteria: * 1\. Patients who have received prior therapy of an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody; * 2\. Patients who are allergic to monoclonal antibodies or any of its excipients; * 3\. Patients who have received other systems for anti-tumor treatment (e. g., Steroid therapy, immunotherapy) within 4 weeks or enrolled in other clinical trials; * 4\. Patients who are pregnant or…